CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host two CME-accredited satellite symposia adjunct to the 2019 AUA Annual Meeting. These programs will be held at McCormick Place West in Chicago, Illinois, on May 3 and 4.
“We look forward to presenting two innovative live educational activities at this year’s annual urology meeting,” said Phil Talamo, president of PER®. “the AUA meeting is an invaluable opportunity for urologists to collaborate and discuss the most pressing clinical questions, evolving data sets, and challenges in patient care when it comes to renal cell carcinoma and bladder cancer.”
The PER® satellite symposia are:
- Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting, will be held as a breakfast symposium on Friday, May 3, from 8-9:30 a.m. in W375B on level 3. The program will be chaired by Robert A. Figlin, M.D., FACP, Steven Spielberg Family Chair in Hematology-Oncology, director of the division of hematology/oncology, deputy director of integrated oncology service line and a professor of medicine and biomedical sciences at Cedars-Sinai Medical Center. During this program, a multidisciplinary panel of renowned experts in renal cell carcinoma (RCC) will guide attendees through an in-depth, up-to-date review of risk assessment in the early-stage RCC setting; surgical standards-of-care and challenges; patient selection for adjuvant systemic therapy; evidence from clinical studies of adjuvant therapy for RCC; and overall multidisciplinary care planning. To register, click here.
- Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward, will be held as a dinner symposium on Saturday, May 4, from 6-8 p.m. in W375A on level 3. The program will be chaired by Daniel P. Petrylak, M.D., professor of medicine and urology, co-director of the Signal Transduction Research Program, Yale Cancer Center, Yale School of Medicine. During this program, a multidisciplinary faculty of renowned experts in urology, medical oncology and immunotherapy will review practice-changing data and discuss their impact on patient care. Brief didactic presentations will be followed by real-world clinical case presentations and discussions to facilitate interpretation and application of the evidence. The faculty will also share their forward-looking perspectives on the bladder cancer treatment horizon based on recently reported and anticipated clinical trial data. To register, click here.
Accredited by the Accreditation Council for Continuing Medical Education (ACCME), each PER® session provides physician attendees with the opportunity to earn up to 2.0 AMA PRA Category 1 Credits™.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.